FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3042370463> ?p ?o ?g. }

• W3042370463 endingPage "2853" @default.
• W3042370463 startingPage "2845" @default.
• W3042370463 abstract "Coronaviruses are enveloped positive-strand RNA viruses belonging to family Coronaviridae and order Nidovirales which cause infections in birds and mammals. Among the human coronaviruses, highly pathogenic ones are Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV) which have been implicated in severe respiratory syndrome in humans. There are no approved antiviral drugs or vaccines for the treatment of human CoV infection to date. The recent outbreak of new coronavirus pandemic, coronavirus disease 2019 (COVID-19) has caused a high mortality rate and infections around the world which necessitates the need for the discovery of novel anti-coronaviral drugs. Among the coronaviruses proteins, 3C-like protease (3CLpro) is an important drug target against coronaviral infection as the auto-cleavage process catalysed by the enzyme is crucial for viral maturation and replication. The present work is aimed at the identification of suitable lead molecules for the inhibition of 3CLpro enzyme via a computational screening of the Food and Drug Administration (FDA) approved antiviral drugs and phytochemicals. Based on binding energies and molecular interaction studies, we shortlisted five lead molecules (both FDA approved drugs and phytochemicals) for each enzyme targets (SARS-CoV-2 3CLpro, SARS-CoV 3CLpro and MERS-CoV 3CLpro). The lead molecules showed higher binding affinity compared to the standard inhibitors and exhibited favourable hydrophobic interactions and a good number of hydrogen bonds with their respective targets. A few promising leads with dual inhibition potential were identified among FDA approved antiviral drugs which include DB13879 (Glecaprevir), DB09102 (Daclatasvir), molecule DB09297 (Paritaprevir) and DB01072 (Atazanavir). Among the phytochemicals, 11,646,359 (Vincapusine), 120,716 (Alloyohimbine) and 10,308,017 (Gummadiol) showed triple inhibition potential against all the three targets and 102,004,710 (18-Hydroxy-3-epi-alpha-yohimbine) exhibited dual inhibition potential. Hence, the proposed lead molecules from our findings can be further investigated through in vitro and in vivo studies to develop into potential drug candidates against human coronaviral infections." @default.
• W3042370463 created "2020-07-23" @default.
• W3042370463 creator A5016283313 @default.
• W3042370463 creator A5024788703 @default.
• W3042370463 creator A5036711466 @default.
• W3042370463 creator A5042263029 @default.
• W3042370463 creator A5076684255 @default.
• W3042370463 date "2020-09-01" @default.
• W3042370463 modified "2023-09-23" @default.
• W3042370463 title "Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme" @default.
• W3042370463 cites W1971849220 @default.
• W3042370463 cites W1981737096 @default.
• W3042370463 cites W1991415701 @default.
• W3042370463 cites W1996259826 @default.
• W3042370463 cites W2003159914 @default.
• W3042370463 cites W2009313526 @default.
• W3042370463 cites W2070633848 @default.
• W3042370463 cites W2074473216 @default.
• W3042370463 cites W2076484749 @default.
• W3042370463 cites W2087363345 @default.
• W3042370463 cites W2092969802 @default.
• W3042370463 cites W2105637133 @default.
• W3042370463 cites W2105649494 @default.
• W3042370463 cites W2105668062 @default.
• W3042370463 cites W2131988685 @default.
• W3042370463 cites W2134967712 @default.
• W3042370463 cites W2147421370 @default.
• W3042370463 cites W2169678694 @default.
• W3042370463 cites W2187960689 @default.
• W3042370463 cites W2244208996 @default.
• W3042370463 cites W2306794997 @default.
• W3042370463 cites W2479595413 @default.
• W3042370463 cites W2538584349 @default.
• W3042370463 cites W2560178450 @default.
• W3042370463 cites W2789775952 @default.
• W3042370463 cites W2890282227 @default.
• W3042370463 cites W2903899730 @default.
• W3042370463 cites W2949305189 @default.
• W3042370463 cites W2985346127 @default.
• W3042370463 cites W3003217347 @default.
• W3042370463 cites W3004280078 @default.
• W3042370463 cites W3011920985 @default.
• W3042370463 cites W3016620140 @default.
• W3042370463 cites W3020076836 @default.
• W3042370463 cites W3023032970 @default.
• W3042370463 cites W41083760 @default.
• W3042370463 cites W4211138079 @default.
• W3042370463 cites W4212923926 @default.
• W3042370463 cites W4323898372 @default.
• W3042370463 doi "https://doi.org/10.1016/j.jksus.2020.07.007" @default.
• W3042370463 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7366079" @default.
• W3042370463 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32837113" @default.
• W3042370463 hasPublicationYear "2020" @default.
• W3042370463 type Work @default.
• W3042370463 sameAs 3042370463 @default.
• W3042370463 citedByCount "29" @default.
• W3042370463 countsByYear W30423704632020 @default.
• W3042370463 countsByYear W30423704632021 @default.
• W3042370463 countsByYear W30423704632022 @default.
• W3042370463 crossrefType "journal-article" @default.
• W3042370463 hasAuthorship W3042370463A5016283313 @default.
• W3042370463 hasAuthorship W3042370463A5024788703 @default.
• W3042370463 hasAuthorship W3042370463A5036711466 @default.
• W3042370463 hasAuthorship W3042370463A5042263029 @default.
• W3042370463 hasAuthorship W3042370463A5076684255 @default.
• W3042370463 hasBestOaLocation W30423704631 @default.
• W3042370463 hasConcept C103637391 @default.
• W3042370463 hasConcept C142724271 @default.
• W3042370463 hasConcept C159047783 @default.
• W3042370463 hasConcept C181199279 @default.
• W3042370463 hasConcept C2522874641 @default.
• W3042370463 hasConcept C2776230035 @default.
• W3042370463 hasConcept C2776714187 @default.
• W3042370463 hasConcept C2776844884 @default.
• W3042370463 hasConcept C2777494893 @default.
• W3042370463 hasConcept C2777648638 @default.
• W3042370463 hasConcept C2779134260 @default.
• W3042370463 hasConcept C2779756493 @default.
• W3042370463 hasConcept C2780035454 @default.
• W3042370463 hasConcept C3008058167 @default.
• W3042370463 hasConcept C524204448 @default.
• W3042370463 hasConcept C55493867 @default.
• W3042370463 hasConcept C71924100 @default.
• W3042370463 hasConcept C74187038 @default.
• W3042370463 hasConcept C86803240 @default.
• W3042370463 hasConcept C98274493 @default.
• W3042370463 hasConceptScore W3042370463C103637391 @default.
• W3042370463 hasConceptScore W3042370463C142724271 @default.
• W3042370463 hasConceptScore W3042370463C159047783 @default.
• W3042370463 hasConceptScore W3042370463C181199279 @default.
• W3042370463 hasConceptScore W3042370463C2522874641 @default.
• W3042370463 hasConceptScore W3042370463C2776230035 @default.
• W3042370463 hasConceptScore W3042370463C2776714187 @default.
• W3042370463 hasConceptScore W3042370463C2776844884 @default.
• W3042370463 hasConceptScore W3042370463C2777494893 @default.
• W3042370463 hasConceptScore W3042370463C2777648638 @default.
• W3042370463 hasConceptScore W3042370463C2779134260 @default.
• W3042370463 hasConceptScore W3042370463C2779756493 @default.

• next